Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population_老虎社区_美港股上老虎

Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population

Reuters2021-03-16

March 16 (Reuters) - :Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population.

Moderna - Study Will Evaluate Safety, Tolerability & Effectiveness Of Two Doses Of Mrna-1273 In Pediatric Participants Given 28 Days Apart.

Moderna - Phase 2/3 Mrna-1273 Study Expected To Enroll 6,750 Healthy Pediatric Participants With Ages 6 Months To Less Than 12 Years In U.S. & Canada.Further Company Coverage: Mrna.O.

((Reuters.Briefs@Thomsonreuters.Com;)).

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

BevG
·2021-03-16
[开心]
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2119786479?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-03-16 18:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2119786479","market":"hk","top_or_hot":-1,"title":"Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population","media":"Reuters","content":"<p>March 16 (Reuters) - :Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population.</p>\n<p>Moderna - Study Will Evaluate Safety, Tolerability &amp; Effectiveness Of Two Doses Of Mrna-1273 In Pediatric Participants Given 28 Days Apart.</p>\n<p>Moderna - Phase 2/3 Mrna-1273 Study Expected To Enroll 6,750 Healthy Pediatric Participants With Ages 6 Months To Less Than 12 Years In U.S. &amp; Canada.Further Company Coverage: Mrna.O. </p>\n<p>((Reuters.Briefs@Thomsonreuters.Com;)).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population\n</h2>\n\n<h4 class=\"meta\">\n\n2021-03-16 18:59 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 16 (Reuters) - :Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population.\nModerna - Study Will Evaluate Safety, Tolerability & ...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":null,"article_id":"2119786479","we_media_id":"1086160438","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2119786479","pubTimestamp":1615892347,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"summary":"March 16 (Reuters) - :Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vacc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"Moderna宣布首批儿童Covid-19候选疫苗2/3期研究参与者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"March 16 (Reuters) - :Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population.\nModerna - Study Will Evaluate Safety, Tolerability & Effectiveness Of Two Doses Of Mrna-1273 In Pediatric Participants Given 28 Days Apart.\nModerna - Phase 2/3 Mrna-1273 Study Expected To Enroll 6,750 Healthy Pediatric Participants With Ages 6 Months To Less Than 12 Years In U.S. & Canada.Further Company Coverage: Mrna.O. \n((Reuters.Briefs@Thomsonreuters.Com;)).","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":325658159,"gmtCreate":1615897215371,"gmtModify":1703494643538,"author":{"id":"3568770848498679","authorId":"3568770848498679","authorIdStr":"3568770848498679","name":"BevG","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3568770848498679"},"htmlText":"[开心]&nbsp;","listText":"[开心]&nbsp;","text":"[开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/325658159","repostId":2119786479,"repostType":4,"repost":{"id":"2119786479","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1615892347,"share":"https://www.laohu8.com/m/news/2119786479?lang=&edition=full","pubTime":"2021-03-16 18:59","market":"hk","language":"en","title":"Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population","url":"https://stock-news.laohu8.com/highlight/detail?id=2119786479","media":"Reuters","summary":"March 16 (Reuters) - :Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vacc","content":"<p>March 16 (Reuters) - :Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population.</p>\n<p>Moderna - Study Will Evaluate Safety, Tolerability &amp; Effectiveness Of Two Doses Of Mrna-1273 In Pediatric Participants Given 28 Days Apart.</p>\n<p>Moderna - Phase 2/3 Mrna-1273 Study Expected To Enroll 6,750 Healthy Pediatric Participants With Ages 6 Months To Less Than 12 Years In U.S. &amp; Canada.Further Company Coverage: Mrna.O. </p>\n<p>((Reuters.Briefs@Thomsonreuters.Com;)).</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-16 18:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>March 16 (Reuters) - :Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population.</p>\n<p>Moderna - Study Will Evaluate Safety, Tolerability &amp; Effectiveness Of Two Doses Of Mrna-1273 In Pediatric Participants Given 28 Days Apart.</p>\n<p>Moderna - Phase 2/3 Mrna-1273 Study Expected To Enroll 6,750 Healthy Pediatric Participants With Ages 6 Months To Less Than 12 Years In U.S. &amp; Canada.Further Company Coverage: Mrna.O. </p>\n<p>((Reuters.Briefs@Thomsonreuters.Com;)).</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2119786479","content_text":"March 16 (Reuters) - :Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population.\nModerna - Study Will Evaluate Safety, Tolerability & Effectiveness Of Two Doses Of Mrna-1273 In Pediatric Participants Given 28 Days Apart.\nModerna - Phase 2/3 Mrna-1273 Study Expected To Enroll 6,750 Healthy Pediatric Participants With Ages 6 Months To Less Than 12 Years In U.S. & Canada.Further Company Coverage: Mrna.O. \n((Reuters.Briefs@Thomsonreuters.Com;)).","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}